Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, newly diagnosed or relapsed MALT, marginal zone lymphoma, or low-grade B cell lymphoproliferative disorder which is CD5-, CD10- and CD20+~* Pathology must be reviewed at Brigham \& Women's Hospital, Massachusetts General Hospital, or the University of Rochester James P. Wilmot Cancer Center prior to enrollment~* Documentation of CD20+ status~* Must not be a candidate for local radiotherapy with curative intent~* If gastric MALT, not a candidate for antibiotic therapy with curative intent~* Patients with leukemic phase marginal zone lymphoma are eligible if their absolute lymphocyte count is \>10,000 / µl~* Prior treatment with rituximab is permitted, if rituximab induced an objective response which persisted for at least 6 months~* Prior radiotherapy is acceptable~* Measurable disease~* ANC: \> 1000/mm3~* Platelets: \> 100,000/mm3~* Hemoglobin: \> 7 gm/dL~* Adequate renal function as indicated by serum creatinine \<= 2 mg/dL.~* Adequate liver function, as indicated by serum total bilirubin \<= 2 mg/dL.~* AST or ALT \<3x Upper Limit of Normal unless related to primary disease.~* Men and women of reproductive potential must agree to use an acceptable method of birth control during study treatment and for six months after completion of study treatment.~* WHO Performance status \</= 2~* Subject has provided written informed consent.~Exclusion Criteria:~* Patients with Waldenstrom's Macroglobulinemia or lymphoplasmacytic lymphoma are excluded~* History of HIV~* Active infection~* Known CNS disease~* Pregnant (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment) or currently lactating women~* Prior treatment within the last three weeks~* Prior fludarabine~* Positive direct antiglobulin test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fludarabine and Rituximab (Type: EXPERIMENTAL): Fludarabine:~25 mg/m2 on days 1-5 of 28 day cycle up to 6 cycles~Rituximab:~375 mg/m2 on day 1 of 28 day cycle up to 6 cycles Rituximab dose was split between days 1 and 3 for patients with absolute lymphocyte counts \> 10x10\^9/L~Patients received three cycles of therapy followed by re-staging with chest/ abdomen/ pelvic CT scan. Patients with progressive disease discontinued treatment. Patients with stable or responding disease continued therapy for another 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).